P2.01. NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IB-III ALK+ NSCLC - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Jay Lee
Meta Tag
Speaker Jay Lee
Topic Local-Regional NSCLC: Novel Therapies & Trials
NAUTIKA1 study
neoadjuvant alectinib
ALK non-small cell lung cancer
major pathological response
platinum-based chemotherapy
adverse events
R0 resections
treatment-related adverse event
Powered By